OmniAb to Report Third Quarter 2026 Financial Results on October 30Business Wire · Oct 14, 2026
OmniAb Investor Day Spotlights Royalty Pipeline, OmniTides Launch and xPloration GrowthMarketBeat · Oct 7, 2026
OmniAb, Inc. (OABI) Analyst/Investor Day TranscriptSeeking Alpha · Oct 6, 2026
All You Need to Know About OmniAb, Inc. (OABI) Rating Upgrade to BuyZacks Investment Research · Oct 6, 2026
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst DayGuruFocus · Oct 6, 2026
OmniAb Highlights Partner Pipeline, xPloration® Plans and Outlook, and Introduces the OmniTides™ Platform at Investor & Analyst DayBusiness Wire · Oct 6, 2026OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.12 | -$0.05 | Beat |
| May 7, 2026 | -$0.10 | -$0.06 | Beat |
| Mar 4, 2026 | -$0.08 | -$0.11 | Miss |
| Nov 4, 2025 | -$0.14 | -$0.14 | Miss |
| Aug 6, 2025 | -$0.14 | -$0.15 | Miss |
| May 8, 2025 | -$0.17 | -$0.17 | Beat |